The evidence emerged from the TOURANDOT trial encourages evaluating the role of anthropometric determinants on treatment outcomes in HER2-negative metastatic breast cancer patients treated with bevacizumab-including regimens. We thus analyzed data from a subgroup of these patients from a larger cohort previously assessed for treatment outcomes. Patients were included in the present analysis if body mass index values had been recorded at baseline. Clinical benefit rates, progression free survival and overall survival were assessed for the overall study population and subgroups defined upon molecular subtype. One hundred ninety six patients were included (N:196). Body mass index showed no impact on clinical benefit rates in the overall study sample and in the luminal cancer subset (p = 0.12 and p = 0.79, respectively), but did so in the triple negative subgroup, with higher rates in patients with body mass index ≥25 (p = 0.03). In the overall study sample, body mass index did no impact progression free or overall survival (p = 0.33 and p = 0.67, respectively). Conversely, in triple negative patients, progression free survival was significantly longer with body mass index ≥25 (6 vs 14 months, p = 0.04). In this subset, overall survival was more favorable (25 vs 19 months, p = 0.02). The impact of the molecular subtype was confirmed in multivariate models including the length of progression free survival, and number of metastatic sites (p < 0.0001). Further studies are warranted to confirm our findings in more adequately sized, ad hoc, prospective studies.

Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab / Pizzuti, L.; Sergi, D.; Sperduti, I.; Lauro, L. D.; Mazzotta, M.; Botti, C.; Izzo, F.; Marchetti, L.; Tomao, S.; Marchetti, P.; Natoli, C.; Grassadonia, A.; Gamucci, T.; Mentuccia, L.; Magnolfi, E.; Vaccaro, Andrea; Cassano, A.; Rossi, E.; Botticelli, A.; Sini, V.; Sarobba, M. G.; Fabbri, M. A.; Moscetti, L.; Astone, A.; Michelotti, A.; De Angelis, C.; Bertolini, I.; Angelini, F.; Ciliberto, G.; Maugeri-Sacca, M.; Giordano, A.; Barba, M.; Vici, P.. - In: CANCER BIOLOGY & THERAPY. - ISSN 1538-4047. - 19:4(2018), pp. 328-334. [10.1080/15384047.2017.1416938]

Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab

Pizzuti L.
Primo
;
Sperduti I.;Mazzotta M.;Marchetti L.;Tomao S.;Marchetti P.;Mentuccia L.;Botticelli A.;Sini V.;Fabbri M. A.;Angelini F.;
2018

Abstract

The evidence emerged from the TOURANDOT trial encourages evaluating the role of anthropometric determinants on treatment outcomes in HER2-negative metastatic breast cancer patients treated with bevacizumab-including regimens. We thus analyzed data from a subgroup of these patients from a larger cohort previously assessed for treatment outcomes. Patients were included in the present analysis if body mass index values had been recorded at baseline. Clinical benefit rates, progression free survival and overall survival were assessed for the overall study population and subgroups defined upon molecular subtype. One hundred ninety six patients were included (N:196). Body mass index showed no impact on clinical benefit rates in the overall study sample and in the luminal cancer subset (p = 0.12 and p = 0.79, respectively), but did so in the triple negative subgroup, with higher rates in patients with body mass index ≥25 (p = 0.03). In the overall study sample, body mass index did no impact progression free or overall survival (p = 0.33 and p = 0.67, respectively). Conversely, in triple negative patients, progression free survival was significantly longer with body mass index ≥25 (6 vs 14 months, p = 0.04). In this subset, overall survival was more favorable (25 vs 19 months, p = 0.02). The impact of the molecular subtype was confirmed in multivariate models including the length of progression free survival, and number of metastatic sites (p < 0.0001). Further studies are warranted to confirm our findings in more adequately sized, ad hoc, prospective studies.
Bevacizumab-including regimens; BMI; first-line treatment; HER2-negative metastatic breast cancer; triple negative subtype; adult; aged; aged, 80 and over; antineoplastic combined chemotherapy protocols; Bevacizumab; breast neoplasms; female; humans; Kaplan-Meier estimate; middle aged; Paclitaxel; progression-free survival; receptor, ErbB-2; body mass index
01 Pubblicazione su rivista::01a Articolo in rivista
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab / Pizzuti, L.; Sergi, D.; Sperduti, I.; Lauro, L. D.; Mazzotta, M.; Botti, C.; Izzo, F.; Marchetti, L.; Tomao, S.; Marchetti, P.; Natoli, C.; Grassadonia, A.; Gamucci, T.; Mentuccia, L.; Magnolfi, E.; Vaccaro, Andrea; Cassano, A.; Rossi, E.; Botticelli, A.; Sini, V.; Sarobba, M. G.; Fabbri, M. A.; Moscetti, L.; Astone, A.; Michelotti, A.; De Angelis, C.; Bertolini, I.; Angelini, F.; Ciliberto, G.; Maugeri-Sacca, M.; Giordano, A.; Barba, M.; Vici, P.. - In: CANCER BIOLOGY & THERAPY. - ISSN 1538-4047. - 19:4(2018), pp. 328-334. [10.1080/15384047.2017.1416938]
File allegati a questo prodotto
File Dimensione Formato  
Pizzuti_Body-mass-index_2018.pdf

accesso aperto

Note: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902232/
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 478.86 kB
Formato Adobe PDF
478.86 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1317192
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 10
social impact